GLP-1s in 2026: the price fell, the access gap did not

Executive summary

Twelve months ago, the GLP-1 access debate was about price. Payers said the medicines worked but cost too much for the number of people who qualified. That argument has now changed shape. US prices have fallen sharply, two oral medicines are approved, and semaglutide generics are on sale in India. Yet in most of Europe, a person living with obesity still pays for treatment themselves.

The central finding

The cost-effectiveness question is mostly answered. The budget question is not. Every major payer that has said yes has also limited who gets treated, how fast, and through which door. The binding constraint on GLP-1 access in 2026 is affordability at population scale, not value per patient.

This piece looks at where the main HTA and payer systems stand in October 2026, what each has actually decided, and what that means for anyone building the evidence for the next obesity launch.

United States: price set by negotiation, not by HTA

The US has no national HTA body, so its price reset came from two other routes. On 6 November 2025, the White House announced agreements with Eli Lilly and Novo Nordisk. Medicare and Medicaid would pay $245 a month for Ozempic, Wegovy, Mounjaro and Zepbound. Cash prices through TrumpRx would fall to around $350 for semaglutide and an average of $346 for Zepbound.^[1]

Three weeks later, CMS published the second round of Inflation Reduction Act negotiated prices. Semaglutide was on the list: $274 a month for Ozempic against a list price of $959, and $385 for higher-dose Wegovy, from 2027.^[5]

Coverage followed price. The Medicare GLP-1 Bridge started on 1 July 2026. Eligible Part D beneficiaries pay a $50 copay for Wegovy (injection or tablet), Zepbound and Foundayo. The bridge runs until 31 December 2027, while CMS collects utilisation data for its longer-term BALANCE model.^[6] That is a payer buying evidence on real-world uptake before committing to a permanent design. HTA bodies in Europe would recognise the logic.

England: a positive recommendation, rationed by rollout

NICE recommended tirzepatide for obesity in December 2024 (TA1026).^[7] The appraisal was positive. The implementation was not simple. NHS England negotiated a funding variation: access will reach the full eligible population over a maximum of 12 years, with priority cohorts set by clinical need. About 220,000 people are expected to be treated in the first three years.^[2]

The first primary care cohort, from 23 June 2025, needed a BMI of 40 or more and at least four of five named comorbidities: hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease and type 2 diabetes. The BMI threshold is usually 2.5 kg/m² lower for people from some ethnic backgrounds.^[2]

This is what a "yes" looks like when the budget impact is large. The ICER cleared the threshold. The phasing is how the system absorbs the bill.

England also became a reference-pricing story. In August 2025, Lilly announced a UK list price rise for Mounjaro from September, with the highest dose going from £122 to £330 a month. NHS prices were unchanged. Lilly said its UK price had been set well below the European average and needed to be aligned to "ensure fair global contributions to the cost of innovation".^[8] With most-favoured-nation pricing now part of US policy, low European list prices are a liability for manufacturers. Expect more of this.

France: the first EU country to pay

From 15 June 2026, French national health insurance reimburses Wegovy and Mounjaro for severe or complicated obesity: a BMI of 40 or more, or 35 or more with comorbidities. The standard rate is 65%, rising to 100% in some cases. Treatment must be started by specialists in approved obesity care structures, and GPs can continue it. The government estimates up to one million people could be eligible, and an annual cost of about €100 million once prescribing scales up.^[3]

France shows the same pattern as England, with a different lever. England limits access through time. France limits it through who can start treatment.

Germany: the law decides before the evidence does

Germany is the clearest example of a system where the HTA question never gets asked. Section 34 of the Social Code Book V has excluded "lifestyle" medicines, including those for weight regulation, since 2004. In March 2024, the G-BA formally added Wegovy to the lifestyle list. Patient groups asked for an exception for severe obesity. The G-BA said the statutory exclusion left it no discretion, and that Wegovy could not be included in the new obesity disease management programme.^[9]

Semaglutide for type 2 diabetes is covered. Semaglutide for obesity is not. The molecule is the same, but the legal category is different. Until the law changes, no amount of cost-effectiveness evidence will move this.

Ireland: close on value, far on budget

Ireland's National Centre for Pharmacoeconomics assessed tirzepatide for weight management in late 2025. It found the drug was not value for money at the submitted price. NCPE clinical director Professor Michael Barry said it was "not too far away" from cost-effective, but that the five-year cost of more than €5.2 billion was too high. Up to 900,000 people could qualify on a BMI over 30 with other factors, against about 80,000 with a BMI over 40.^[10]

The NCPE advice set up a policy choice, not a technical one: fund a smaller, higher-need group, or wait for a lower price. For now, Saxenda (liraglutide) is the only weight-loss injection the HSE funds for public patients.^[10]

Pills and patents: the price floor is moving

Two oral medicines are now approved in the US. The FDA approved oral semaglutide 25 mg (Wegovy tablets) on 22 December 2025. In OASIS 4, mean weight loss was 13.6% against 2.2% for placebo in the treatment-policy analysis.^[11] Lilly's orforglipron (Foundayo) followed in April 2026, with 11.1% weight loss against 2.1% for placebo across doses in ATTAIN-1. Self-pay starts at $149 a month.^[12]

Oral delivery matters to payers for reasons beyond convenience. Small molecules are cheaper and easier to manufacture at scale, and they remove the injection-pen supply constraint that has shaped rationing since 2023.

At the same time, semaglutide's core patent expired in India around 20 March 2026. Sun Pharma, Dr Reddy's, Zydus, Mankind and Lupin announced generic brands, and analysts expect more than 50 brands from over 40 companies. Core patents also expire by the end of 2026 in Canada, Brazil, China, South Africa and Turkey. In the US, UK and most of Europe, protection runs to 2031 or later.^[13]

For European HTA bodies, this creates an awkward comparator problem. The same molecule will soon be sold at generic prices in large markets, while the European list price still reflects patent protection. Expect payers to use that gap in negotiations, and expect manufacturers to argue for next-generation products with outcomes data.

Global health: a guideline ahead of the supply

On 1 December 2025, WHO issued its first guideline on GLP-1 medicines for obesity. It made a conditional recommendation for long-term use of liraglutide, semaglutide and tirzepatide in adults. The conditional rating reflects limited long-term data, uncertainty about stopping treatment, cost, health system readiness and equity. WHO had added GLP-1 therapies to its Essential Medicines List in September 2025 for type 2 diabetes in high-risk groups.^[4]

The most striking line in the release is the projection. Even with rapid growth in production, these medicines are expected to reach fewer than 10% of the people who could benefit by 2030. WHO points to pooled procurement, tiered pricing and voluntary licensing, and plans a prioritisation framework during 2026.^[4]

What this means in practice

For HEOR and market access teams, the GLP-1 story is now a budget-impact story. Five things follow.

• Model the rollout, not just the ICER: England's 12-year phasing and France's specialist-initiation rule are both ways of controlling the budget curve. Submissions that show a credible, phased uptake scenario make that easier for payers.
• Get the eligible population right: Ireland's estimate ran from about 80,000 to 900,000 people depending on the criteria. That range decides the outcome more than the cost per QALY does.
• Treat discontinuation as a core input: WHO cited uncertainty about stopping treatment as a reason for its conditional rating. Weight regain after stopping drives long-run value, and committees will test it.
• Plan for international reference pricing: US MFN pricing and the UK list price increase show that a low price in one market now affects others. Launch sequencing and confidential discounts matter more.
• Watch the generic semaglutide price: It will become a reference point for payers, even where it cannot yet be sold. Value stories for newer agents will need outcomes data, not just weight loss.

The bottom line

Most payers now agree GLP-1s are clinically effective and, at the right price, cost-effective. The fight has moved to who gets treated first, how fast the rest follow, and what the price will be once generics and pills arrive. That is a different evidence problem, and the next round of submissions should be built for it.

References

1. AJMC. Trump announces deals with Eli Lilly, Novo Nordisk for lower weight loss drug prices [Internet]. Cranbury (NJ): AJMC; 2025 Nov 6 [cited 2026 Oct 8]. Available from: https://www.ajmc.com/view/trump-announces-deals-with-eli-lilly-novo-nordisk-for-lower-weight-loss-drug-prices
2. NHS England. Interim commissioning guidance: implementation of NICE TA1026 (tirzepatide). Updated April 2026 [Internet]. London: NHS England; [date unknown] [cited 2026 Oct 8]. Available from: https://www.england.nhs.uk/long-read/interim-commissioning-guidance-nice-ta1026-tirzepatide/
3. The Connexion. Anti-obesity drugs Wegovy and Mounjaro reimbursed in France from Monday [Internet]. Monaco: The Connexion; 2026 Jun 15 [cited 2026 Oct 8]. Available from: https://www.connexionfrance.com/news/anti-obesity-drugs-wegovy-and-mounjaro-reimbursed-in-france-from-monday/796535
4. World Health Organization. WHO issues global guideline on the use of GLP-1 medicines in treating obesity. News release [Internet]. Geneva: World Health Organization; 2025 Dec 1 [cited 2026 Oct 8]. Available from: https://www.who.int/news/item/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity
5. Fierce Pharma. Medicare unveils price reductions for 15 drugs, including Novo's semaglutide [Internet]. Framingham (MA): Fierce Pharma; 2025 Nov 26 [cited 2026 Oct 8]. Available from: https://www.fiercepharma.com/pharma/medicare-unveils-price-reductions-15-drugs-including-novos-semaglutide
6. Forbes Health. What to know about Medicare's GLP-1 subsidy program launching July 1 [Internet]. Jersey City (NJ): Forbes Health; 2026 [cited 2026 Oct 8]. Available from: https://www.forbes.com/health/weight-loss/medicare-glp1-coverage-changes-medicaid-lmandp5/
7. National Institute for Health and Care Excellence. Tirzepatide for managing overweight and obesity [TA1026] [Internet]. London: National Institute for Health and Care Excellence; 2024 Dec [cited 2026 Oct 8]. Available from: https://www.nice.org.uk/guidance/ta1026
8. Associated Press. Eli Lilly hikes Mounjaro prices in the UK to make weight-loss drug cheaper in the US [Internet]. New York (NY): Associated Press; 2025 Aug 15 [cited 2026 Oct 8]. Available from: https://abc17news.com/news/2025/08/15/eli-lilly-hikes-mounjaro-prices-in-the-uk-to-make-weight-loss-drug-cheaper-in-the-us/
9. Gemeinsamer Bundesausschuss. G-BA vollzieht den gesetzlichen Verordnungsausschluss für das Abmagerungsmittel Wegovy nach [Internet]. Berlin: Gemeinsamer Bundesausschuss; 2024 Mar 21 [cited 2026 Oct 8]. Available from: https://www.g-ba.de/presse/pressemitteilungen-meldungen/1170/
10. Irish Examiner. HSE told €5.2bn cost of Mounjaro weight-loss drug is too high to fund for most patients [Internet]. Cork: Irish Examiner; 2025 Dec 4 [cited 2026 Oct 8]. Available from: https://www.irishexaminer.com/news/arid-41754225.html
11. Applied Clinical Trials. FDA approves oral Wegovy following positive OASIS trial results [Internet]. Cranbury (NJ): Applied Clinical Trials; 2025 Dec 23 [cited 2026 Oct 8]. Available from: https://www.appliedclinicaltrialsonline.com/view/fda-approves-oral-wegovy-positive-oasis-trial-results
12. PharmaShots. Eli Lilly reports US FDA approval of Foundayo (orforglipron) for weight loss [Internet]. [place unknown]: PharmaShots; 2026 Apr 2 [cited 2026 Oct 8]. Available from: https://pharmashots.com/32510/eli-lilly-reports-us-fda-approval-of-foundayo-orforglipron-for-weight-loss/
13. Pharmacy Business. Semaglutide patent expiry in India to trigger a wave of cheaper generics [Internet]. London: Pharmacy Business; 2026 Mar 20 [cited 2026 Oct 8]. Available from: https://www.pharmacy.biz/semaglutide-patent-expiry-india-generics/

This article reflects public information available on 7 October 2026 and Evidaxia's independent analysis. It is not medical, legal or investment advice.